EUR 0.23
(0.09%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 52.98 Million EUR | -30.15% |
2022 | 75.84 Million EUR | -33.82% |
2021 | 114.6 Million EUR | -19.44% |
2020 | 142.26 Million EUR | 0.0% |
2019 | - EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 FY | 52.98 Million EUR | -30.15% |
2023 Q4 | 52.98 Million EUR | 0.0% |
2023 Q2 | 82.28 Million EUR | 0.0% |
2023 Q1 | 82.28 Million EUR | 8.49% |
2022 Q4 | 75.84 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
European Medical Solutions | 43.75 Million EUR | -21.075% |
FERMENTALG | 50.24 Million EUR | -5.445% |
argenx SE | 4.11 Billion EUR | 98.712% |
BioSenic S.A. | 9.55 Million EUR | -454.242% |
Celyad Oncology SA | 16.28 Million EUR | -225.39% |
Hyloris Pharmaceuticals SA | 47.68 Million EUR | -11.113% |
Onward Medical N.V. | 43.62 Million EUR | -21.433% |
Oxurion NV | 6.55 Million EUR | -708.855% |
PHAXIAM Therapeutics S.A. | 51.3 Million EUR | -3.261% |
Financière de Tubize SA | 1.92 Billion EUR | 97.241% |
UCB SA | 15.53 Billion EUR | 99.659% |